EH

European Heart Journal - Cardiovascular Pharmacotherapy

European Heart Journal – Cardiovascular Pharmacotherapy is an ESC Publications journal focused on cardiovascular medicine and pharmacology. It became fully Open Access from January 2025, with all accepted submissions from 3 September 2024 publishing under an Open Access license. The journal reports a 2024 Impact Factor of 6.1 and a 2024 CiteScore of 11.2.

Looking to publish in European Heart Journal - Cardiovascular Pharmacotherapy? Livewrite integrates seamlessly with Word to help you write, edit, and format faster.

Existing customer login
Subject Cardiac & Cardiovascular Systems, Pharmacology & Pharmacy
Impact Factor 6.1
Quartile Q1
Open Access Type Open
ISSN 2055-6837
eISSN 2055-6845
Invitation Only No
Cost Range An Article Processing Charge may be payable for accepted submissions publishing in the 2025 volume; the journal has no submission fees, offers a 20% APC discount for eligible ESC members, and partial or full waivers may be available for corresponding authors in eligible LMIC countries.

Submission Instructions

European Heart Journal - Cardiovascular Pharmacotherapy accepts the following article types. Click on an article type to view submission instructions.

Original Articles

Cover Letter Cover letter is required to disclose any use of AI at submission and to identify if an EHJ-CVP Editor is a co-author or contributor. Cover letter must disclose any use of AI and indicate if an EHJ-CVP Editor is a co-author or contributor.
Abstract Abstract is required. Abstract must not exceed 250 words. Abstract must be structured. Abstract must use the headings aims, methods and results, and conclusion.
Manuscript Manuscript must not exceed 5000 words including references, figure legends, and tables. Manuscript text must be arranged in the order title page, abstract and keywords, introduction, methods, results, discussion, acknowledgements, references, appendices, text tables, and figure legends. Manuscript must include no more than six keywords, a Funding section before Acknowledgements, a Disclosures section, an explanation of any AI use in Methods or Acknowledgements, and a graphical abstract legend in the Legends section if a graphical abstract is submitted.
References References are limited to a maximum of 50. References must use Vancouver style. References must be cited with Arabic numerals in order of appearance, use Medline journal abbreviations, include complete citation information, and list the first six authors followed by "et al." when there are more than six authors.
Figures & Tables Figures and tables are limited to a combined total of 8, with any additional items designated as supplementary online-only material. Figures must be submitted as separate files, each table must be uploaded as a separate file, and graphical abstracts must be submitted as a separate file for peer review. A separate list of figure legends must be included in the manuscript file, alt text must be provided for all images, and a graphical abstract legend defining any abbreviations must be included in the Legends section of the manuscript.
Reformat to European Heart Journal - Cardiovascular Pharmacotherapy using Livewrite Premium

Reviews

Cover Letter Cover letter is required only to disclose AI use at submission and to indicate if an EHJ-CVP Editor is a co-author or contributor. Cover letter must disclose any use of AI and must indicate if an EHJ-CVP Editor is a co-author or contributor.
Abstract Abstract is required. Abstract must not exceed 250 words. Abstract must be structured. Abstract must use the headings Aims, Methods and results, and Conclusion.
Manuscript Review articles must not exceed 5000 words excluding references and the text in figure legends and tables. Manuscript text must be arranged in the order title page, abstract and keywords, introduction, methods, results, discussion, acknowledgements, references, appendices, text tables, and figure legends. Manuscript must include no more than six keywords, a Disclosures section, a Funding section, and an explanation of any AI use in a Methods or Acknowledgements section.
References References must use Vancouver style. References must be cited by Arabic numerals in order of appearance, use Medline journal abbreviations, include complete citation details, and list the first six authors followed by "et al." when there are more than six authors.
Figures & Tables Standard submissions must include no more than 8 total figures and tables, with any additional items submitted as supplementary online-only material. Figures, tables, and graphical abstracts must be uploaded as separate files, and the graphical abstract legend must be included in the Legends section of the manuscript. Graphical abstracts are encouraged and must be submitted as a separate file for peer review, sized 12.5 × 18.0 cm, with text in a sans serif font at 10–12 points and no smaller than 8 points.
Reformat to European Heart Journal - Cardiovascular Pharmacotherapy using Livewrite Premium

Correspondence

Cover Letter AI use must be disclosed in the cover letter, and if an EHJ-CVP Editor is a co-author or contributor this must also be indicated. Cover letter must disclose any AI use and must indicate if an EHJ-CVP Editor is a co-author or contributor.
Abstract Abstract must not be included.
Manuscript Manuscript must not exceed 1000 words including references, figure legends, and tables. Manuscript must not contain sub-headings. Manuscript must include no abstract and, if AI was used, a full explanation in the Methods or Acknowledgements section.
References References are limited to 10. References must use Vancouver style. References must be cited by Arabic numerals in order of appearance, with journal titles abbreviated according to Medline and more than six authors shortened to the first six followed by "et al.".
Figures & Tables A maximum of 1 figure or table is allowed. Figures must be submitted as separate files and each table must be uploaded as a separate file. A separate list of figure legends must be included in the text file, and tables must be supplied in an editable format.
Reformat to European Heart Journal - Cardiovascular Pharmacotherapy using Livewrite Premium

Letters

Cover Letter AI use must be disclosed in the cover letter at submission, and if an EHJ-CVP Editor is a co-author or contributor this must also be stated there. Cover letter must disclose any use of AI and must indicate if an EHJ-CVP Editor is a co-author or contributor.
Abstract Abstract must not be included.
Manuscript Manuscript must not exceed 1000 words including references, figure legends, and tables. Manuscript must not contain sub-headings. Manuscript must include a full explanation of any AI use in the Methods or Acknowledgements section.
References References must not exceed 10. References must use Vancouver style. References must be cited in the text with Arabic numerals in citation order, and if there are more than six authors list the first six followed by "et al.".
Figures & Tables No more than 1 figure or table may be included. Figures must be submitted as separate files from the main manuscript, tables must each be uploaded as separate files, and figure legends must be included in the text file as a separate list.
Reformat to European Heart Journal - Cardiovascular Pharmacotherapy using Livewrite Premium

Rapid Communications

Cover Letter AI use must be disclosed in the cover letter at submission, and if an EHJ-CVP Editor is a co-author or contributor this must also be indicated in the cover letter. Cover letter must disclose any use of AI and must indicate if an EHJ-CVP Editor is a co-author or contributor.
Abstract Abstracts are not permitted for Rapid Communications.
Manuscript Manuscript must not exceed 1,000 words excluding the title, abstracts, legends, and references. Manuscript text must be arranged in the order: title page, abstract and keywords, introduction, methods, results, discussion, acknowledgements, references, appendices, text tables, figure legends. Manuscript may include up to 6 keywords or phrases, must explain any use of AI in a Methods or Acknowledgements section, and must include the specified Editor disclosure statement in a section entitled "Disclosures" when applicable.
References References are limited to 10. References must use Vancouver style. References must be cited by Arabic numerals in order of appearance, journal titles must be abbreviated according to Medline, and if there are more than six authors the first six must be listed followed by "et al.".
Figures & Tables Rapid Communications may include 1 figure or table or video, and figures may include up to 6 panels. Figures must be submitted as separate files from the main manuscript and each table must be uploaded as a separate file. Supplementary material is not permitted for Rapid Communications.
Reformat to European Heart Journal - Cardiovascular Pharmacotherapy using Livewrite Premium

Recent Publications

Repositioning Vericiguat after VICTOR: Towards a Risk- and Timing-Based Framework in Contemporary HFrEF

Teruhiko Imamura

10.1093/ehjcvp/pvag092
View Publication

Analysis and Interpretation of a Hierarchical Outcome in a Small Pilot Randomized Trial: An Example in the CORTAHF Trial

Jan Biegus, Christopher Edwards, Gary Koch, Gad Cotter, Yonathan Freund, Adriaan A Voors, Koji Takagi, Piotr Ponikowski, Gerasimos Filippatos, Ovidiu Chioncel, Matteo Pagnesi, Marco Metra, Douglas L Mann, Beth Davison

10.1093/ehjcvp/pvag089
View Publication

Refining cardiovascular pharmacotherapy in cardio-oncology and cardiac amyloidosis: news from ESC Congress 2026

Massimiliano Camilli, Marianna Fontana, Pietro Ameri

10.1093/ehjcvp/pvag088
View Publication

Nebivolol for the Prevention of Left Ventricular Systolic Dysfunction in Patients With Duchenne Muscular Dystrophy: the NEBIDYS trial

Luca Monzo, Henri-Marc Becane, Yves Dulac, Helge Amthor, Claude Cances, Aurélie Chalard, Jean-Baptiste Davion, Isabelle Desguerre, Isabelle Durand, Sylvie Falcon-Eicher, Sophie Guillaumont, Arnaud Isapof, Fabien Labombarda, Léa Jilet, Hendy Abdoul, Denis Duboc, Karim Wahbi

10.1093/ehjcvp/pvag090
View Publication

Same Target but Different Bleeding Outcomes: Insights from a Randomized Apixaban-Rivaroxaban Comparison in Patients with Acute Venous Thromboembolism

Jean-Luc Reny, Youssef Daali, Jean Terrier

10.1093/ehjcvp/pvag087
View Publication

Frequently asked questions

How long does it take to publish?

First decision within an average of 9 days. Accepted manuscripts are aimed to be published on Advance Access within 2 days of receipt at OUP if the licence to publish is signed promptly. Proof corrections must be returned within 3 days.

Reformat to European Heart Journal - Cardiovascular Pharmacotherapy using Livewrite Premium

Is a cover letter required?

A cover letter is used in specific situations. Authors should indicate in the cover letter if an Editor or Associate Editor from the journal is a co-author or contributor, and AI use should be disclosed in a cover letter at submission.

Reformat to European Heart Journal - Cardiovascular Pharmacotherapy using Livewrite Premium

What are the publication costs?

An Article Processing Charge may be payable. The journal has no submission fees. Eligible ESC members receive a 20% APC discount, and partial or full APC waivers may be available for corresponding authors in eligible LMIC countries.

Reformat to European Heart Journal - Cardiovascular Pharmacotherapy using Livewrite Premium

Research Topics

Atrial Fibrillation Management and Outcomes Antiplatelet Therapy and Cardiovascular Diseases Acute Myocardial Infarction Research Heart Failure Treatment and Management Lipoproteins and Cardiovascular Health Diabetes Treatment and Management Venous Thromboembolism Diagnosis and Management Coronary Interventions and Diagnostics Health Systems, Economic Evaluations, Quality of Life Cardiac electrophysiology and arrhythmias Blood Pressure and Hypertension Studies Cardiac Imaging and Diagnostics Cardiac Arrhythmias and Treatments Cardiovascular Function and Risk Factors Diabetes, Cardiovascular Risks, and Lipoproteins Cardiac, Anesthesia and Surgical Outcomes COVID-19 Clinical Research Studies Potassium and Related Disorders Medication Adherence and Compliance Cardiac pacing and defibrillation studies Acute Ischemic Stroke Management Cardiac Health and Mental Health Hormonal Regulation and Hypertension Vitamin K Research Studies Hyperglycemia and glycemic control in critically ill and hospitalized patients

Related Journals

AO
Annals of Thoracic Medicine Medknow
CT
Cardiovascular Toxicology Springer Science+Business Media
DD
Drug Delivery Taylor & Francis
CI
Clinical Infectious Diseases Oxford University Press
IA
Infection and Drug Resistance Dove Medical Press
TJ
The Journal of Infectious Diseases Oxford University Press